Description
TRUST COLOXEASE TAB, offered by Pharmacor Pty Ltd, is a specialized medicinal product designed to alleviate constipation through its dual-action formula. Each film-coated tablet functions as both a faecal softener and a stimulant laxative, providing effective relief for those in need.
Active Ingredients
- Docusate Sodium (50 mg): Acts as a faecal softener, making bowel movements more comfortable.
- Sennosides (10 mg): Serves as a stimulant laxative, encouraging bowel activity.
Usage Instructions
- Recommended for Adults and Children Aged 12 and Over: Take 1 or 2 tablets at night, with the option to increase up to 4 tablets if necessary.
- Not Suitable for Children Under 12: Alternative solutions should be considered for younger children.
- Dietary Recommendations: Users should increase dietary fibre intake and maintain adequate hydration for optimal results.
Special Features
- Gluten Free
- Lactose Free
- Gelatin Free
These features make it suitable for individuals with specific dietary restrictions.
Precautions
- Avoid use if experiencing abdominal pain, nausea, or vomiting.
- Consult a healthcare provider if pregnant, breastfeeding, or if symptoms persist.
- Do not combine with other medications or liquid paraffin without medical advice.
- Prolonged use is discouraged to prevent dependency or bowel issues.
Storage Instructions
- Store Below 25°C
- Protect from Light
With a shelf life of 36 months, proper storage ensures the product remains effective.
Physical Characteristics
The tablets are dark brown, circular, and biconvex, with a plain surface on both sides. They are available in bottles containing 30, 90, or 200 tablets, providing flexible options for different needs.
Regulatory Information
TRUST COLOXEASE TAB is a registered medicine in Australia, with ARTG (AUST R) number 250052. It is not scheduled as a controlled medicine and may not require a prescription, though consultation with a pharmacist is advised. Additionally, it is listed on the Repatriation Schedule of Pharmaceutical Benefits (RPBS) as of May 1, 2025.
This comprehensive profile ensures that users are well-informed about the product, enabling them to make educated decisions regarding their healthcare needs.
